Flash Finance

Vineet Laboratories LimitedVINEETLABCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 14 quarters of data
₹39.01
MCap ₹75 Cr · P/E 67.8
Vineet Laboratories Limited — Stock analysis & AI research Vineet Laboratories Limited — Seasonality — best & worst months Vineet Laboratories Limited — Technical setup — score, trend, support & resistance Vineet Laboratories Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹19 Cr
Sales · Mar 2026
+34.2% YoY
₹2 Cr
Operating Profit · Mar 2026
+122.6% YoY
13.2%
OPM % · Mar 2026
+116.8% YoY
₹1 Cr
Net Profit · Mar 2026
+106.9% YoY
₹0.43
EPS · Mar 2026
+107.8% YoY

📝 Vineet Laboratories Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Vineet Laboratories Limited reported revenue of ₹19 crore for the quarter ended March 2026 (Q4 FY26), up 34.2% from ₹14 crore in the same quarter last year, and up 20.7% sequentially over the December 2025 quarter.

The company swung to a net profit of ₹1 crore from a net loss of ₹11 crore a year earlier. Earnings per share (EPS) came in at ₹0.43.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 13.2%, compared with -78.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Vineet Laboratories Limited posted revenue of ₹59 crore, a decline of 20.8% over FY25, with a net profit of ₹1 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹59 crore with a net profit of ₹1 crore.

Valuation snapshot

At the current price of ₹39.01, VINEETLAB has a market capitalisation of ₹75 crore and a trailing P/E of about 67.8.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 5.98%, foreign institutional investors (FIIs) 0.50%, public shareholders 93.52% of Vineet Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹75 Cr
Current Price ?
₹39.0
P/E ?
67.80above ind
Industry P/E ?
37.20
P/B ?
1.64
P/S ?
1.26
P/FCF ?
N/A
Enterprise Value ?
₹120 Cr
EV/EBITDA ?
14.21
PEG ?
N/A
Earnings Yield ?
5.0%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹59 Cr
OPM ?
14.3%
Profit after tax (TTM) ?
₹1 Cr
EPS (TTM) ?
₹0.58
ROCE ?
-28.0%
ROE ?
2.4%
ROA ?
0.9%
Growth
Sales — latest qtr ?
₹19 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
34.2%
YoY qtr profit growth ?
106.9%
Sales growth (3y) ?
-27%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹45 Cr
Debt to Equity ?
0.99
Interest Coverage ?
1.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
5.98%
Change in promoter holding ?
-23.28%
Pledged percentage ?
N/A
Market
Return 3 months ?
5.5%
Return 6 months ?
11.3%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 675738433337241918147171619 +34.2% +20.7%
Operating Profit 2604-13-1-0-4-110322 +122.6% +0.6%
Other Income 00000000010000 -97.8% -40.4%
Interest 10111211111211 +10.2% -9.0%
Depreciation 11111111111111 -18.4% -14.5%
Profit Before Tax 05-13-21-2-2-6-11-1011 +108.9% +22.8%
Net Profit 14-12-22-2-2-6-11-1011 +106.9% -14.7%
EPS 0.721.85-0.651.26-1.081.00-1.11-0.95-2.97-5.48-0.450.210.440.43 +107.8% -2.3%
OPM % 2.9% 10.2% 0.7% 9.6% -2.0% 9.2% -3.3% -1.6% -22.8% -78.4% 4.2% 18.3% 15.8% 13.2% +116.8% -16.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹75 Cr ₹59 Cr ₹59 Cr -20.8%
Operating Profit ₹-16 Cr ₹8 Cr ₹8 Cr +152.0%
OPM % -21.69% 14.25% 14.25% +165.7%
NPM % -26.93% 1.86% 1.86% +106.9%
Other Income ₹2 Cr ₹0 Cr ₹0 Cr -94.5%
Depreciation ₹3 Cr ₹2 Cr ₹2 Cr -3.2%
Interest ₹4 Cr ₹5 Cr ₹5 Cr +22.6%
EBIT ₹-19 Cr ₹6 Cr ₹6 Cr +132.1%
PBT ₹-21 Cr ₹1 Cr ₹1 Cr +106.1%
Tax — ₹0 Cr ₹0 Cr —
Net Profit ₹-20 Cr ₹1 Cr ₹1 Cr +105.5%
EPS ₹-10.51 ₹0.63 ₹0.63 +106.0%
Material Cost — ₹23 Cr ₹23 Cr —
Employee Cost — ₹1 Cr ₹1 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 5 periods)

Metric Mar 2023Mar 2024Mar 2025Sep 2025Mar 2026 % Chg
Equity Capital 999919 +113.4%
Reserves 24265526 +428.0%
Borrowings 3144404345 +5.4%
Other Liabilities 5138403434 -0.4%
Total Liabilities 1161179591125 +37.1%
Fixed Assets 2727252424 +1.0%
CWIP 0000— —
Investments 00000 —
Other Assets 89906966100 +52.0%
Total Assets 1161179591125 +37.1%

💧 Cash Flow (latest 5 periods)

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 8-10-711-12 -209.4%
Cash from Investing Activity -4-7-2-3-1 +63.0%
Cash from Financing Activity 1208-830 +471.7%
Net Cash Flow 16-16-0017 —
Free Cash Flow 8-17-910— —
CFO/OP 82%-87%-88%-71%— —

➗ Ratios (latest 4 periods)

Metric Mar 2022Mar 2023Mar 2024Mar 2025 % Chg
Debtor Days 69607764 -16.9%
Inventory Days 10998158260 +64.6%
Days Payable 16174103175 +69.9%
Cash Conversion Cycle 1784131150 +14.5%
Working Capital Days -192128-37 -232.1%
ROCE % 23%9%7%-28% -500.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 29.26%15.89%12.46%5.98%5.98% +0.0%
FIIs 0.00%0.00%0.00%0.36%0.50% +38.9%
Public 70.74%84.11%87.54%93.67%93.52% -0.2%
No. of Shareholders 9,9889,68210,0039,9299,901 -0.3%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 VINEETLAB Vineet Laboratories ₹36.78 71 56.1 59 1 14.3% 1.9% -20.8% 105.5% 34.2% 106.9%
❓ Frequently asked questions
What was Vineet Laboratories Limited's revenue in Q4 FY26?
Vineet Laboratories Limited reported revenue of ₹19 crore for the quarter ended March 2026 (Q4 FY26), up 34.2% from ₹14 crore in the same quarter last year, and up 20.7% sequentially over the December 2025 quarter.
What was Vineet Laboratories Limited's net profit in Q4 FY26?
The company swung to a net profit of ₹1 crore from a net loss of ₹11 crore a year earlier. Earnings per share (EPS) came in at ₹0.43.
What is VINEETLAB's market capitalisation and P/E ratio?
At the current price of ₹39.01, VINEETLAB has a market capitalisation of ₹75 crore and a trailing P/E of about 67.8.
Who owns Vineet Laboratories Limited? (shareholding pattern)
As of Jun 2026, promoters held 5.98%, foreign institutional investors (FIIs) 0.50%, public shareholders 93.52% of Vineet Laboratories Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI